Teva Pharmaceutical Industries Ltd. (TEVA Quick QuoteTEVA - Free Report) reported $4.14 billion in revenue for the quarter ended June 2026, representing a year-over-year decline of 0.8%. EPS of $0.02 for the same period compares to $0.66 a year ago.

The reported revenue represents a surprise of +1.43% over the Zacks Consensus Estimate of $4.08 billion. With the consensus EPS estimate being $0.08, the EPS surprise was -75%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Teva Pharmaceutical Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Geographic Revenue- International Markets- AJOVY: $49 million compared to the $31 million average estimate based on two analysts. The reported number represents a change of +145% year over year.
• Geographic Revenue- United States- Other: $84 million versus the two-analyst average estimate of $112.5 million. The reported number represents a year-over-year change of -24.3%.
• Geographic Revenue- International Markets- COPAXONE: $8 million compared to the $7.25 million average estimate based on two analysts. The reported number represents a change of +14.3% year over year.
• Geographic Revenue- International Markets- Generic products (including OTC and biosimilars): $419 million versus the two-analyst average estimate of $425.38 million. The reported number represents a year-over-year change of +2.2%.
• Geographic Revenue- International Markets- Other: $55 million compared to the $60.65 million average estimate based on two analysts. The reported number represents a change of 0% year over year.
• Geographic Revenue- Europe- AJOVY: $78 million compared to the $79.05 million average estimate based on two analysts. The reported number represents a change of +9.9% year over year.
• Geographic Revenue- Europe- COPAXONE: $49 million versus the two-analyst average estimate of $38.75 million. The reported number represents a year-over-year change of -2%.
• Geographic Revenue- Europe- Generic products (including OTC and biosimilars): $1.02 billion versus $1.1 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -1.5% change.
• Geographic Revenue- Europe- Other: $54 million versus $82.6 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -33.3% change.
• Geographic Revenue- Europe- Respiratory products: $58 million versus $57.59 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.5% change.
• Geographic Revenue- United States: $1.7 billion versus $1.65 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -20.9% change.
• Geographic Revenue- Europe: $1.26 billion compared to the $1.36 billion average estimate based on two analysts. The reported number represents a change of -2.7% year over year.

View all Key Company Metrics for Teva Pharmaceutical Industries here>>>

Shares of Teva Pharmaceutical Industries have returned -6.5% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.